Precigen to Host R&D Update Virtual Event on December 15th to Share Latest Clinical Developments

GERMANTOWN, Md., Dec. 8, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company will host a virtual event on Tuesday, December 15, 2020 at 11:00 AM ET to provide an update on the latest progress for its clinical pipeline.

The event will showcase data from several of the Company's most advanced clinical programs, such as PRGN-3005 UltraCAR-T(®), PRGN-3006 UltraCAR-T(®) and AG019 ActoBiotics(TM). Precigen executives and key opinion leaders will participate in the event, including:

    --  Helen Sabzevari, PhD, President and CEO of Precigen
    --  Pieter Rottiers, PhD, CEO of Precigen ActoBio
    --  Mary L. (Nora) Disis, MD, faculty member at the University of Washington
        and Fred Hutchinson Cancer Research Center and one of the lead
        investigators for the PRGN-3005 clinical study
    --  Kevan Herold, MD, Professor of Immunobiology and of Medicine
        (Endocrinology) at Yale School of Medicine and one of the lead
        investigators for the AG019 clinical study

Participants may register and access the live webcast through Precigen's investor relations website in the Press & Events section. An archived recording will be posted to the investor relations website following the event.

Precigen: Advancing Medicine with Precision((TM)
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit or follow us on Twitter @Precigen and LinkedIn.

Precigen, Advancing Medicine with Precision, UltraCAR-T, and ActoBiotics are trademarks of Precigen and/or its affiliates. Other names may be trademarks of their respective owners.

Cautionary Statement Regarding Forward-Looking Statements
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T therapies, and the Company's refocus to a healthcare-oriented business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, including the possibility that the timeline for the Company's clinical trials might be impacted by the COVID-19 pandemic, and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

For more information, contact:

              Investor Contact:       
              Media Contact:

     Steven Harasym                     
     Glenn Silver

     Vice President, Investor Relations 
     Lazar-FINN Partners

     Tel: +1 (301) 556-9850             


View original content to download multimedia:

SOURCE Precigen, Inc.